AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
chenodiol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4361 | 474-25-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.19 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 5.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.42 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 13 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 28, 1983 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A05AA01 | ALIMENTARY TRACT AND METABOLISM BILE AND LIVER THERAPY BILE THERAPY Bile acids and derivatives |
| FDA CS | M0002475 | Bile Acids and Salts |
| MeSH PA | D002400 | Cathartics |
| MeSH PA | D005765 | Gastrointestinal Agents |
| FDA EPC | N0000175802 | Bile Acid |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
A05AA Bile acids and derivatives 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Calculus in biliary tract | indication | 266474003 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Obstruction of bile duct | contraindication | 30144000 | |
| Primary biliary cirrhosis | contraindication | 31712002 | DOID:12236 |
| Diarrhea | contraindication | 62315008 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Sclerosing cholangitis | contraindication | 235917005 | DOID:14268 |
| Pregnancy, function | contraindication | 289908002 | |
| Gallstone Complications | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.92 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 250MG | CTEXLI | MIRUM | N219488 | Feb. 21, 2025 | RX | TABLET | ORAL | Feb. 21, 2028 | NEW PRODUCT |
| 250MG | CTEXLI | MIRUM | N219488 | Feb. 21, 2025 | RX | TABLET | ORAL | Feb. 21, 2032 | TREATMENT OF CEREBROTENDINOUS XANTHOMATOSIS (CTX) IN ADULTS |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bile acid receptor | Nuclear hormone receptor | AGONIST | EC50 | 5.47 | CHEMBL | CHEMBL | |||
| fMet-Leu-Phe receptor | GPCR | ANTAGONIST | Ki | 4 | IUPHAR | ||||
| G-protein coupled bile acid receptor 1 | GPCR | AGONIST | EC50 | 5.40 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 0GEI24LG0J | UNII |
| 4022365 | VUID |
| D00163 | KEGG_DRUG |
| N0000146754 | NUI |
| 4018428 | VANDF |
| 4022365 | VANDF |
| C0008024 | UMLSCUI |
| CHEBI:16755 | CHEBI |
| JN3 | PDB_CHEM_ID |
| CHEMBL240597 | ChEMBL_ID |
| 10133 | PUBCHEM_CID |
| DB06777 | DRUGBANK_ID |
| 4391 | INN_ID |
| 2323 | RXNORM |
| 25632 | MMSL |
| d07268 | MMSL |
| 001208 | NDDF |
| 82490009 | SNOMEDCT_US |
| 89132005 | SNOMEDCT_US |
| D002635 | MESH_DESCRIPTOR_UI |
| 608 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Chenodiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0722-7121 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 19 sections |
| Chenodal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68974-876 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 20 sections |
| CTEXLI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 79378-310 | TABLET, FILM COATED | 250 mg | ORAL | NDA | 28 sections |
| Chenodiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 79739-7121 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 19 sections |